Ginsenoside F3

Name: Ginsenoside F3
Brand: MedChemExpress
SKU: HY-N0600
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0600 Purity: 99.84%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a K_d value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.

For research use only. We do not sell to patients.

Ginsenoside F3 Chemical Structure

CAS No. : 62025-50-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[2]

IL-2

IL-4

IL-10

NF-κB

In Vitro

Ginsenoside F3 (0.1-100 μmol/L; 72 h) significantly enhances Concanavalin A (HY-P2149)-induced murine spleen cell proliferation, with the maximal 87.2% increase occurring at 10 μmol/L^[1].
Ginsenoside F3 (0.1-100 μmol/L; 48 or 72 h) increases Concanavalin A-induced IL-2 and IFN-γ production and decreases ConA-induced IL-4 and IL-10 production in murine spleen cells, with maximal effects at 10 μmol/L^[1].
Ginsenoside F3 (0.1-100 μmol/L; 10 h) upregulates Concanavalin A-induced IFN-γ and T-bet mRNA expression and downregulates ConA-induced IL-4 and GATA-3 mRNA expression in murine spleen cells^[1].
Ginsenoside F3 (10 μmol/L; 1 h) enhances Concanavalin A-induced NF-κB DNA binding activity in murine spleen cells^[1].
Ginsenoside F3 directly binds to RIPOR2 with a binding affinity of 3.77 μM^[2].
Ginsenoside F3 (0.1-10 μM; day 4 and day 6 of chronic stimulation) dose-dependently reduces the frequency of PD-1⁺ TIM-3⁺ exhausted primary mouse CD8⁺ T cells under chronic anti-CD3 stimulation, and restores RIPOR2 expression in these cells^[2].
Ginsenoside F3 (0.1-10 μM; 6 days) dose-dependently restores TNF-α and IFN-γ cytokine production in exhausted primary mouse CD8⁺ T cells cultured under chronic anti-CD3 stimulation for 6 days^[2].
Ginsenoside F3 (1-10 μM; 48 h) significantly promotes the proliferation of Jurkat T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	Jurkat T cells
Concentration:	0.1, 1, 10, 100 μM
Incubation Time:	48 h
Result:	Significantly increased Jurkat T cell proliferation at 1 and 10 μM, with the 10 μM dose yielding the largest increase (~20% higher absorbance than untreated controls). Showed a trend toward increased proliferation at 0.1 μM. Showed reduced proliferation relative to the 10 μM dose but remained above control levels at 100 μM.

Cell Viability Assay^[2]

Cell Line:	H1299, A549, and Lewis lung carcinoma (LLC) cells
Concentration:	0.1, 1, 10, 100 μM
Incubation Time:	24, 48, or 72 h
Result:	Showed no significant cytotoxic effect on H1299, A549, or LLC cells at concentrations ≤ 10 μM at any incubation time. Showed a modest inhibitory effect on A549 and H1299 cells (≤ 20% reduction in viability) after 72 h at 100 μM. Showed no significant effect on LLC cells at any dose or time point.

In Vivo

Ginsenoside F3 (5 mg/kg; i.p.; daily; 28 days) alone reduces NSCLC tumor burden and increases intratumoral CD4⁺ T cell infiltration, and synergizes with anti-PD-1 therapy to further reduce tumor burden and enhance CD8⁺ T cell infiltration in the tumor microenvironment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 J mice (male, 6-8 weeks old, 20-30 g, intravenous tail vein injection of 4 × 10⁶ LLC cells)^[2]
Dosage:	5 mg/kg
Administration:	i.p.; daily; 28 days
Result:	Reduced mean lung tumor weight to 0.457 g, compared to 0.907 g in the model group. Increased the proportion of CD4⁺ T cells among tumor-infiltrating CD3⁺ lymphocytes to 28.1%, compared to 19.5% in the model group.

Molecular Weight

770.99

Formula

C₄₁H₇₀O₁₃

CAS No.

62025-50-7

Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO[C@H](OC[C@H](O)[C@@H]6O)[C@@H]6O)([H])CC4)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (129.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2970 mL	6.4852 mL	12.9703 mL
5 mM	0.2594 mL	1.2970 mL	2.5941 mL
10 mM	0.1297 mL	0.6485 mL	1.2970 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.84%

Select Batch:

Data Sheet (287 KB) SDS (254 KB)

COA (260 KB) HNMR (331 KB) RP-HPLC (86 KB)

Handling Instructions (2659 KB)

References

[1]. Yu JL. Immunoenhancing activity of protopanaxatriol-type ginsenoside-F3 in murine spleen cells. Acta Pharmacol Sin. 2005;25(12):1671-6.

[2]. Jiang M, et al. Ginsenoside F3 alleviates T cell exhaustion via RIPOR2-mediated immunometabolic reprogramming to potentiate anti-PD-1 therapy. Phytomedicine. 2026;150:157649.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2970 mL	6.4852 mL	12.9703 mL	32.4258 mL
	5 mM	0.2594 mL	1.2970 mL	2.5941 mL	6.4852 mL
	10 mM	0.1297 mL	0.6485 mL	1.2970 mL	3.2426 mL
	15 mM	0.0865 mL	0.4323 mL	0.8647 mL	2.1617 mL
	20 mM	0.0649 mL	0.3243 mL	0.6485 mL	1.6213 mL
	25 mM	0.0519 mL	0.2594 mL	0.5188 mL	1.2970 mL
	30 mM	0.0432 mL	0.2162 mL	0.4323 mL	1.0809 mL
	40 mM	0.0324 mL	0.1621 mL	0.3243 mL	0.8106 mL
	50 mM	0.0259 mL	0.1297 mL	0.2594 mL	0.6485 mL
	60 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5404 mL
	80 mM	0.0162 mL	0.0811 mL	0.1621 mL	0.4053 mL
	100 mM	0.0130 mL	0.0649 mL	0.1297 mL	0.3243 mL

Ginsenoside F3 Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ginsenoside F3

Customer Review

Ginsenoside F3 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Ginsenoside F3 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ginsenoside F3 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report